Reviewed 11 May 2026

Completeness Good (58%)

PET/CT Image Analysis Software - PET Neurology

United Imaging Intelligence

PET/CT Image Analysis Software is intended to be used by medical staff like radiologists and technicians who work in nuclear medicine department, for the purpose of assisting in the analysis of neurodegenerative disease.

No papers to support — we monitor for new evidence.

Key Features

  • Brain parcellation
  • Centiloid scaling
  • Quantitative analysis
  • Report generation

General Information

Product name

PET/CT Image Analysis Software - PET Neurology

Modality

PET

Main task

Quantification

Subspeciality

Neuro

Disease targeted

Neurodegenerative diseases

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Verified by Health AI Register

Other certifications

Not specified

Evidence & Research

No research papers or evidence on file yet.

The registry monitors publications for new evidence.

Technical Specifications

Patient population age

Adult, Elderly

Input

Brain PET/CT scans

Input format

DICOM

Output

Registered PET and CT images, PET MIP image, segmentation of brain regions, regional SUV, regional SUVr, regional Z-score, Centiloid, screenshot, report

Output format

Not specified

Integration

Integration in standard reading environment (PACS), Stand-alone third party application, Stand-alone webbased

Deployment

Cloud-based, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, right after the image acquisition

Processing time

Not specified

Population

Contraindications match standard PET/CT. FDG-PET contraindications: 1) contrast allergy; 2) renal insufficiency; 3) inability to remain still ~20 min; 4) poorly controlled diabetes; 5) pregnancy; 6) infancy. Amyloid PET is inappropriate when: 1) probable AD already confirmed; 2) non-diagnostic use; 3) asymptomatic high-risk individuals; 4) unverified cognitive complaints; 5) suitable alternatives exist. Use with caution where not clinically validated: 1) intracranial mass; 2) poor image quality (e.g., high noise or motion) 3) newborns (<1 year).

Market Presence

On market since

08-2025

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

One-time license fee, Pay-per-use, Subscription

Based on

Number of analyses, Number of installations, Number of users

First published: Oct 22, 2025 | Last updated: May 11, 2026